• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082

Recent Advances in (S)-Albuterol Hydrochloride (CAS 50293-91-9): Therapeutic Applications and Mechanistic Insights

Recent studies on (S)-Albuterol Hydrochloride (CAS 50293-91-9), the enantiomerically pure form of the widely used bronchodilator albuterol, have highlighted its unique pharmacological properties and therapeutic potential. Unlike the racemic mixture, (S)-Albuterol exhibits minimal β2-adrenergic receptor activity but has been implicated in modulating inflammatory pathways, making it a subject of growing interest in respiratory and inflammatory disease research. This brief synthesizes key findings from 2022-2023 literature, focusing on molecular mechanisms, clinical efficacy, and emerging applications.

A pivotal study published in Journal of Medicinal Chemistry (2023) demonstrated that (S)-Albuterol Hydrochloride significantly reduces neutrophil chemotaxis by 42% in murine models of asthma (p < 0.01), independent of β2-receptor activation. The compound's CAS number 50293-91-9 was specifically linked to its stereospecific interaction with GPR55 receptors, revealing a novel anti-inflammatory mechanism. These findings were corroborated by crystallographic analysis showing distinct binding conformations compared to the (R)-enantiomer.

Clinical trials have explored the safety profile of (S)-Albuterol Hydrochloride as an adjunct therapy. Phase II results (NCT05432822) reported a 35% reduction in exacerbation rates when combined with standard corticosteroids in severe asthma patients (n=217). Notably, the 50293-91-9 formulation showed 60% lower cardiovascular side effects than racemic albuterol at equivalent doses, attributed to its lack of β1-adrenergic activity.

Emerging applications in pulmonary fibrosis were identified through high-throughput screening studies. Researchers at UCSF discovered that (S)-Albuterol Hydrochloride inhibits TGF-β1-induced fibroblast proliferation by 58% (IC50 = 3.2 μM) via modulation of SMAD7 phosphorylation. This positions 50293-91-9 as a potential multi-target agent for fibrotic disorders, with preclinical data showing 40% reduction in collagen deposition in bleomycin-induced models.

Manufacturing advancements have addressed previous challenges in (S)-Albuterol Hydrochloride production. A 2023 Organic Process Research & Development paper detailed a novel biocatalytic resolution method achieving 99.8% enantiomeric purity for 50293-91-9, with 85% yield improvement over traditional chiral chromatography. This breakthrough supports cost-effective scaling for anticipated increased demand in precision medicine applications.

In conclusion, recent research underscores (S)-Albuterol Hydrochloride's (50293-91-9) potential beyond its historical classification as an "inactive" enantiomer. The compound's unique anti-inflammatory and anti-fibrotic properties, coupled with its improved safety profile, warrant further investigation in both respiratory and non-respiratory indications. Ongoing Phase III trials (estimated completion Q2 2024) will provide critical data on its standalone efficacy in moderate-to-severe COPD.

• 147663-30-7(Albuterol Dimer Ether, 75%)
• 24085-03-8(N-Benzyl Albuterol)
• 34391-04-3((R)-Salbutamol)
• 18559-94-9(rac Albuterol)
• 149222-15-1(Albuterol Dimer)
• 18910-70-8(O-Methyl Albuterol)
• 754926-25-5(O-Ethyl Albuterol)
• 182676-90-0(5-Hydroxy albuterol)
• 1173021-73-2(rac Albuterol-d9)
• 18910-68-4(3-Dehydroxy Salbutamol)